Target Validation Information | |||||
---|---|---|---|---|---|
TTD ID | T35940 | ||||
Target Name | ERK activator kinase 1 (MEK1) | ||||
Type of Target |
Clinical trial |
||||
Drug Potency against Target | 4,5-Dibromo-1H-pyrrole-2-carboxylic acid amide | Drug Info | IC50 = 2500 nM | [1] | |
5-phenylamino-4-cyano-3-hydroxy-isothiazole | Drug Info | IC50 = 7000 nM | [2] | ||
ALDISIN | Drug Info | IC50 = 2500 nM | [1] | ||
DEBROMOHYMENIALDISINE | Drug Info | IC50 = 2500 nM | [1] | ||
OROIDIN | Drug Info | IC50 = 2500 nM | [1] | ||
REVERSINE | Drug Info | IC50 = 8 nM | [3] | ||
References | |||||
REF 1 | Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1). J Med Chem. 2002 Jan 17;45(2):529-32. | ||||
REF 2 | Discovery of 3-hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles as potent MEK1 inhibitors. Bioorg Med Chem Lett. 2006 Aug 1;16(15):3975-80. | ||||
REF 3 | Reversine increases the plasticity of lineage-committed mammalian cells. Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10482-7. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.